Search Results

May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Before joining Inversago, Mr.

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV

January 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation

HTL0039732 Exscientia Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates Postdoc Research Associate Director, Regulatory Affairs Research Scientist/Senior Scientist I - Molecular Pharmacology

Exscientia’s Clinical and Preclinical Development The pathway of opioid drugs into cellular structures Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics (June 4 - 8, 2023). 2023 Molecular Pharmacology (GRS) Seminar GRC. (June 10 - 11, 2023). Adrenoceptors and GPCR Signalling (June 30 - July 1, 2023) 19th World Congress of Basic & Clinical Pharmacology

GPCR Activation and Signaling Molecular Mechanisms of PTH/PTHrP class B GPCR Signaling and Pharmacological Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist June 4-8,2023. 2023 Molecular Pharmacology (GRS) Seminar GRC. June 10 - 11. June 11-16, 2023. 19th World Congress of Basic & Clinical Pharmacology 2023. July 2 - 7.

shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Adrenoceptors and GPCR Signalling (June 30 - July 1, 2023) 19th World Congress of Basic & Clinical Pharmacology GPCRs, Ion Channels, and Transport Proteins (March 24 - 29, 2024) GPCR Jobs Professor in Cardiovascular Pharmacology

Reviews, GPCRs, and more Pharmacological Profiling of a Brugia malayi Muscarinic Acetylcholine Receptor Industry News Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference (June 4 - 8, 2023). 2023 Molecular Pharmacology (GRS) Seminar GRC. (June 10 - 11, 2023). (June 11 - 16, 2023). 19th World Congress of Basic & Clinical Pharmacology 2023. , biophysics of transporters and GPCRs Chief of Staff Postdoctoral Fellow, Biochemical And Cellular Pharmacology

Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology Industry News 'GPCR Therapeutics' latest science paper was published by the American College of Clinical Pharmacology immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business Update Crinetics Pharmaceuticals : Paltusotine Phase 3 Data Presented At ENDO Novo Nordisk to Acquire Inversago Pharma GPCR Events, Meetings Postdoc Research Associate Director, Regulatory Affairs Research Scientist/Senior Scientist I - Molecular Pharmacology

Announces Site Relocation AI can help to speed up drug discovery — but only if we give it the right data Inversago Pharma divulges new cannabinoid CB1 receptor antagonists BenevolentAI, Exscientia on the comeback trail Technician II - Surgery Post-Doc Research Associate Research Technician Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals Postdoc In Cell Biology Of Protein Trafficking Postdoctoral Fellow Explore

GPCR University Today marks the conclusion of the Dr.GPCR University course, ‘Applying Pharmacology to Signaling Mechanisms of G Protein-Coupled Receptors through Structural Biology Industry News INV-347 by Inversago Pharma for Obesity: Likelihood of Approval Septerna to Participate in Upcoming Investor and Industry Conferences Sosei and IPJ to become Nxera Pharma from April Orion Biotechnology will be at the BIO CEO Research Fellow Postdoctoral Fellow – Molecular Pharmacology of Feeding Behavior Director of Laboratory

, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner Monlunabant by Inversago Pharma Likelihood of Approval Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio Addex Pharma 2026 GPCR Jobs HIGHLIGHT Principal Scientist, In vitro pharmacology NEW Post-Doctoral Scientist- Molecular Pharmacology (FDE) NEW Research Assistant Senior Scientist - Receptor Pharmacology Postdoctoral Scientist Senior Research Associate/Associate Scientist, Protein Science Post-Doctoral Fellow—Pharmacology/Cell

This is your chance to get the whole experience of our comprehensive pharmacology courses for less! Topics: Pharmacologic activity measurement, mechanisms of action, and GPCR discovery strategies. GPCR News  Let’s dive into the   Classified GPCR News from September 16th to 22nd, 2024 Industry News Inversago Pharma’s INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder Emerging Voices in GPCR Biology in Special Issue of Molecular Pharmacology GPCR Events, Meetings, and

February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews

January 2022 "We are an experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing medicines for people around the world." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 "February 17, 2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi "San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics Inc. (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, extending its $100 million Series B financing, which was announced in October 2021. In addition, Structure Therapeutics has completed dosing in a single ascending dose (SAD) Phase 1 study of its lead type 2 diabetes and obesity program, GSBR-1290." Read more at the source #DrGPCR #GPCR #IndustryNews

#ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail This week in Terry’s Corner , we go beyond the dose-response curves to explore the kinetic and pharmacologic GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner , scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech #GPCRNews #Science

Scientist—In-vitro Pharm; Postdoc roles. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

synabs #monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals #oncology #healthcare #drugdevelopment" Read more at the source #DrGPCR

When pharmacologists misinterpret how an antagonist interacts with its receptor, the consequences ripple Terry Kenakin reframes one of pharmacology’s most foundational ideas: the difference between competitive Inside the Lesson: Antagonist Behavior by the Numbers Terry walks through both the pharmacologic and novices to expert drug hunters Influence over upcoming topics Who it’s for:  drug discovery teams, pharmacologists If you want to avoid costly misinterpretations and strengthen your pharmacology toolkit, Terry’s Corner

Are you ready to truly understand how pharmacologists predict whole-body drug response from a single straight to it:   Why models are vital for translating lab data into clinical forecasts The 4 types of pharmacologic Elevate your pharmacology expertise. Unlock "Pharmacologic Models" now

GPCR University workshop on Advanced Data Analysis for GPCR Pharmacology, led by the esteemed Dr. GPCR Matchmaking Read Mark's job spotlight article for a Principal Scientist in In Vitro Pharmacology Mark recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals! to atypical chemokine receptor 3 Industry News New cannabinoid CB1 receptor antagonists disclosed in Inversago

GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles of Pharmacology New Course Dates: Principles of Pharmacology I :  October 3, 10, 17, 24 (four sessions) Principles Fast: Don’t miss this incredible opportunity to immerse yourself in the  Principles of Pharmacology and ' Advanced Data Analysis for GPCR Pharmacology' ." GLP-1 drugs’ Opening Ceremony of Xuzhou Zhongshu Research Site and CNS Drug Innovation Forum Nxera Pharma

Breakthroughs this week:  Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma earns $10m milestone from AbbVie neurological deal. 🔍 This Week in Dr. Kenakin — October 30, 12 PM EST Bring your toughest pharmacology questions and join Dr. Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost = GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology Clark , laid the foundation for today’s quantitative pharmacology. Enzyme Inhibition Pharmacology: Orthosteric vs. Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full Pharmacology isn’t just about hitting the receptor—it’s about surviving the enzymes first.

Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein Nxera Pharma and Antiverse partner on GPCRs Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, | BIO International Convention 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology Principal Scientist, Medicinal Chemistry PhD fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

Over the years, we’ve built a global network of researchers, biotech leaders, and pharma innovators who Push the boundaries  of receptor pharmacology and its real-world applications.   📚 Terry’s Corner — The Only On-Demand Pharmacology Hub with Dr. GPCR  community, you already know about Terry’s Corner  — our exclusive, on-demand pharmacology series where Terry Kenakin breaks down receptor pharmacology, functional selectivity, and ligand bias in a